Michael Bigham - May 27, 2021 Form 4 Insider Report for Paratek Pharmaceuticals, Inc. (PRTK)

Role
Exec. Chairman of the Board, Director
Signature
/s/ William M. Haskel, Attorney-in-Fact for Michael Bigham
Stock symbol
PRTK
Transactions as of
May 27, 2021
Transactions value $
-$333,331
Form type
4
Date filed
6/8/2021, 07:28 PM
Previous filing
Sep 21, 2023
Next filing
Jun 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTK Common Stock Award $0 +85.9K +10.38% $0.00 914K May 27, 2021 Direct F1
transaction PRTK Common Stock Sale -$333K -34.4K -3.76% $9.70 879K Jun 4, 2021 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance-based restricted stock units ("PRSUs") granted on February 19, 2020 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on May 27, 2021.
F2 Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.58 to $9.97. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.